Plasminogen activator in normal and tumor-bearing mice
- 15 July 1983
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 32 (1) , 121-126
- https://doi.org/10.1002/ijc.2910320119
Abstract
The plasminogen activator levels of a series of murine tumors commonly used in cancer drug screening were determined and compared to the levels found in normal mouse tissues. Tumors high in plasminogen activator included the B16 and colon 26. The Lewis lung and M5076 carcinoma showed an intermediate level of activity, while the plasminogen activator activity in the L1210 leukemia and colon 38 was barely elevated above background. The specific activity of the enzyme (per μg protein) in extracts of B16 and colon 26 was three or four times higher than in the most active normal organs surveyed (kidney, lung, brain and intestine). The high level of plasminogen activator activity measured in extracts of the B16 tumor was reflected in a substantial elevation of the levels of fibrin degradation products in the serum of mice carrying this tumor. This result suggests that the tumor‐associated plasminogen activator activity is less subject to inhibitory controls in vivo than is the plasminogen activator of most normal tissues, since the total mass of the tumor was far less than the total mass of the fibrinolytically active tissues, and yet the bulk of the fibrin degradation products were caused by the tumor. We conclude that the high levels of plasminogen activator activity which are observed in many human tumors are found only in some of the transplantable murine tumors. Since this enzyme is active at an increased level in vivo in mice carrying the B16 tumor, plasminogen activator may be a suitable target for selective, enzyme‐activated chemotherapy with this tumor test system.This publication has 23 references indexed in Scilit:
- Recent advances in the chemistry of the fibrinolytic systemChemical Reviews, 1981
- HUMAN FIBROBLASTS PRODUCE INHIBITOR DIRECTED AGAINST PLASMINOGEN ACTIVATOR WHEN TREATED WITH GLUCOCORTICOIDS*Annals of the New York Academy of Sciences, 1981
- Protease-activated “prodrugs” for cancer chemotherapyProceedings of the National Academy of Sciences, 1980
- Thromboplastic and fibrinolytic activities of cultured human cancer cell linesBritish Journal of Cancer, 1979
- Co‐cultivation of tumorigenic mouse melanoma cells with cells of a non‐tumorigenic subclone inhibits plasminogen activator expression by the melanoma cellsJournal of Cellular Physiology, 1978
- I-fibrinogen as an oncophilic radiodiagnostic agent: distribution kinetics in tumour-bearing miceBritish Journal of Cancer, 1977
- Measurement of fibrinogen degradation products (FDP) in serum of normal and tumor-bearing rats.The Tohoku Journal of Experimental Medicine, 1975
- Increased Plasminogen Activator (Urokinase) in Tissue Culture After Fibrin DepositionJournal of Clinical Investigation, 1973
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970
- The Fibrinolytic Activity of Animal TissuesActa Physiologica Scandinavica, 1957